Trial Profile
A Phase I - II Open Label Study of the Maximum Tolerated Dose, Safety and Efficacy of Docetaxel and Cisplatin Plus STI571 in Advanced Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2014
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Imatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 29 May 2014 New trial record